Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0M4UZ
|
|||
| Former ID |
DNCL002044
|
|||
| Drug Name |
JNJ-39758979
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8; ICD-9: 493] | Phase 2 | [1] | |
| Company |
Janssen Research & Development
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H19N5
|
|||
| Canonical SMILES |
CC(C)C1=CC(=NC(=N1)N)N2CCC(C2)N
|
|||
| InChI |
1S/C11H19N5/c1-7(2)9-5-10(15-11(13)14-9)16-4-3-8(12)6-16/h5,7-8H,3-4,6,12H2,1-2H3,(H2,13,14,15)/t8-/m1/s1
|
|||
| InChIKey |
COOGVHJHSCBOQT-MRVPVSSYSA-N
|
|||
| CAS Number |
CAS 1046447-90-8
|
|||
| PubChem Compound ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00946569) A Study of the Safety and Effectiveness of JNJ-39758979 in the Treatment of Adults With Persistent Asthma. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.